JNT-517 Tablet

DRUG3 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

PhenylketonuriaPhenylketonuria (PKU)

Phase 1

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

CompletedNCT05781399

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria

Start: 2022-10-31End: 2025-07-14Updated: 2026-05-06

Phase 2

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

CompletedNCT06637514

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria (PKU)

Start: 2025-07-16End: 2026-05-08Updated: 2026-05-13

Phase 3

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

RecruitingNCT06971731

Otsuka Pharmaceutical Development & Commercialization, Inc.Phenylketonuria

Start: 2025-10-20End: 2028-04-01Target: 120Updated: 2026-05-04